Two-Drug cocktail targets Hard-to-Treat hodgkin lymphoma
NCT ID NCT03681561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs—nivolumab and ruxolitinib—together in people whose Hodgkin lymphoma has returned or not responded to treatment. The goal is to find the safest dose of ruxolitinib when combined with a fixed dose of nivolumab, and to see if the combination can control the cancer for at least 3 months. About 54 adults will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) and ruxolitinib (Jakafi)
What this could lead to
If successful, this combination could offer a new treatment option for people with Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 54 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana Melvin and Bren Simon Comprehensive Cancer Center
WITHDRAWNIndianapolis, Indiana, 46202, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Illinois Cancer Center
COMPLETEDChicago, Illinois, 60612, United States
-
University of Iowa Hospitals and Clinics
ACTIVE_NOT_RECRUITINGIowa City, Iowa, 52242, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact